We can’t show the full text here under this license. Use the link below to read it at the source.
GLP-1 receptor agonists in Parkinson’s disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials
GLP-1 receptor drugs and their link to Parkinson's disease progression: a combined analysis of clinical trials
AI simplified
Abstract
Five randomized controlled trials with 708 nondiabetic patients indicated a significant reduction in motor symptom progression in Parkinson's disease with GLP-1 receptor agonists, with a mean difference in MDS-UPDRS Part III of -2.06.
- GLP-1 receptor agonists are associated with a slowing of motor symptom progression in mild-to-moderate Parkinson's disease.
- The primary outcome measured was the change in MDS-UPDRS scores, showing a notable mean difference.
- No significant improvements were found in other aspects of the MDS-UPDRS, medication dosage, or functional scales.
- A trend toward increased serious adverse events or treatment discontinuation was noted but was not statistically significant.
- Further research is needed to clarify the effects on nonmotor symptoms and long-term safety.
AI simplified
Key numbers
-2.06
in Part III
Comparison of GLP-1 RAs vs. placebo in patients off medication.
1.52
for Serious
Comparison of between GLP-1 RAs and placebo groups.
708
Total Patients Included
Total number of nondiabetic patients with mild-to-moderate PD in the analysis.